To include your compound in the COVID-19 Resource Center, submit it here.

WuXi Biologics, TaiMed rise after FDA approves mAb for HIV

WuXi Biologics Inc. (HKSE:2269) climbed HK$3.15 to HK$61.90 on Wednesday after FDA approved Trogarzo ibalizumab-uiyk, a mAb the

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE